Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring.
about
How to manage aspergillosis in non-neutropenic intensive care unit patientsTherapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspectiveFundament and Prerequisites for the Application of an Antifungal TDM ServiceIntensive care medicine research agenda on invasive fungal infection in critically ill patients.Impact of CYP2C19 Genotype and Liver Function on Voriconazole Pharmacokinetics in Renal Transplant Recipients.Voriconazole metabolism, toxicity, and the effect of cytochrome P450 2C19 genotype.CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics?Population pharmacokinetic-pharmacodynamic analysis of voriconazole and anidulafungin in adult patients with invasive aspergillosisTherapeutic drug monitoring of voriconazole: a case report of multiple drug interactions in a patient with an increased CYP2C19 activity.Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes.Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.Impact of hypoalbuminemia on voriconazole pharmacokinetics in critically ill adult patients.Inflammation is associated with voriconazole trough concentrations.Pharmacokinetics and safety of voriconazole intravenous-to-oral switch regimens in immunocompromised Japanese pediatric patients.Variability of voriconazole plasma concentrations after allogeneic hematopoietic stem cell transplantation: impact of cytochrome p450 polymorphisms and comedications on initial and subsequent trough levelsUPLC-MS/MS determination of voriconazole in human plasma and its application to a pharmacokinetic study.Safety of voriconazole and sirolimus coadministration after allogeneic hematopoietic SCT.Influence of inflammation on voriconazole metabolismAchieving target voriconazole concentrations more accurately in children and adolescents.Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis.In vitro study of the variable effects of proton pump inhibitors on voriconazoleA rapid MCM-41 dispersive micro-solid phase extraction coupled with LC/MS/MS for quantification of ketoconazole and voriconazole in biological fluids.The influence of combination use of CYP450 inducers on the pharmacokinetics of voriconazole: a systematic review.Bioassay for Determining Voriconazole Serum Levels in Patients Receiving Combination Therapy with Echinocandins.Voriconazole therapeutic drug monitoring: results of a prematurely discontinued randomized multicenter trial.Therapeutic Drug Monitoring and Genotypic Screening in the Clinical Use of Voriconazole.Software for dosage individualization of voriconazole for immunocompromised patientsA retrospective analysis of patient-specific factors on voriconazole clearance.Voriconazole therapeutic drug monitoring: retrospective cohort study of the relationship to clinical outcomes and adverse events.Potential factors for inadequate voriconazole plasma concentrations in intensive care unit patients and patients with hematological malignanciesNeurologic Adverse Events Associated with Voriconazole Therapy: Report of Two Pediatric CasesTherapeutic drug monitoring in voriconazole-associated hyponatremia.Long term outcome of medical and surgical co-management of craniospinal aspergillosis in an immunocompromised patient.Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology.Safety, Efficacy, and Exposure-Response of Voriconazole in Pediatric Patients With Invasive Aspergillosis, Invasive Candidiasis or Esophageal Candidiasis.Voriconazole in clinical practice.Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis.Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014.Therapeutic drug monitoring in the treatment of invasive aspergillosis with voriconazole in cancer patients--an evidence-based approach.Acid suppressing therapy as a risk factor for Candida esophagitis.
P2860
Q26999448-F6F10542-6DEC-4FD7-AAD8-5CA8AFCEBB46Q27009221-146E79A1-EDCE-4DA7-8F0C-CE7BA740C3C0Q28085352-96B949DA-E1EB-4407-8DCC-445CBA3D2BE4Q30235457-3CC2F919-1CAA-4B70-824C-842D5D1F1144Q30491969-4C866B54-D8AA-46A0-9E67-2EB75DB08B2CQ33684379-C2C963A4-3189-4A74-A87D-E0C9488D0D7DQ33849298-B1F5FE56-D257-4A3A-A5FA-DE5AEA6C4827Q34020402-AC7579BF-29E8-4770-A2D8-20C628FD22C7Q34034599-F62C2106-4635-4217-91F6-502553482A7FQ34138276-7EA5B489-6DDB-41BB-9933-C261656F0C68Q34532546-F26F5DBB-6A9A-4D7A-83B0-1BA7C77FADFCQ34596313-2201ADEE-DF02-4C5B-ACA3-0E78EEB8F4D1Q34597394-7556D751-E0AA-41AD-A87F-AE1131B25774Q35105949-308272CF-C341-4214-A856-FC67DA02B936Q35169112-EB421E29-8C0B-413E-953E-72E1A278DDFAQ35187285-83A9C25A-6894-4CDA-90F8-2B8862292ABFQ35231368-3BD83F19-E2E6-43E5-90C0-BE82D813A6A3Q35386048-575C71E5-FD21-4F41-88DC-10971E052043Q35607652-190F6926-D2E4-410F-AA54-E15A90685A69Q35954530-C20DAEE2-2F3D-43B0-8448-AD71F68D1FCAQ35960842-E9F95AD8-00C1-4648-9948-EFFFCBC1105BQ36090668-6706272A-F140-4BEE-8892-345FCE650A1FQ36273788-C9C7C485-BEE5-4B72-A982-DF62926665FAQ36439011-00DDA334-F259-4C5D-8A03-A636FA4C9C61Q36469807-1F2351B7-E54D-4CA4-9BD0-917F3AD6D269Q36608562-9D64CF5F-EA60-4029-BF51-A04581864E9DQ36757595-69AA731E-0821-4418-9DD9-BDE69375A242Q36810454-53646380-A17F-4982-B0A1-12AD95F12776Q36849416-FE853967-0714-49A6-AD47-DCA7C771F39EQ36969780-4F4C2B6D-9735-47CF-BA0D-27A844D51280Q36974048-04F05E9F-35B6-49E8-B882-E579D1E599FEQ37454178-CDE10F7B-4C84-476B-96FD-281DCBB2E365Q37543967-251D0995-1263-48A1-8104-46B41EC9E795Q37688257-3772DB6B-C982-47DD-B978-214E133A6661Q37693296-EBC01345-1F98-48A1-B23B-E1E137B0E57BQ38061736-6F30E60D-2BE6-4FF2-8A98-7F56C7710188Q38140015-3FD1C12E-79EC-465F-AC2E-ACAD37BDBA81Q38284468-BD6E4B13-FBBE-47F0-8DE2-19ED1A7BF30EQ38362057-814D1B1C-8E92-4B9B-BAD5-A08C6D924721Q38400673-F87B8450-C017-4B51-9431-AA3B31705B43
P2860
Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring.
@ast
Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring.
@en
type
label
Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring.
@ast
Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring.
@en
prefLabel
Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring.
@ast
Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring.
@en
P2093
P2860
P356
P1476
Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring.
@en
P2093
John E Ray
Kingsley Ng
Michael J Dolton
Sharon C-A Chen
P2860
P304
P356
10.1128/AAC.00626-12
P407
P577
2012-07-02T00:00:00Z